Triptorelin

Triptorelin is a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH) with a D-tryptophan substitution at position 6 that increases receptor binding affinity and resistance to enzymatic degradation. This modification transforms the short-acting native GnRH into a long-acting superagonist with paradoxical effects on the pituitary-gonadal axis.

Upon initial administration, triptorelin stimulates the GnRH receptor, causing a transient increase in LH, FSH, and subsequently sex hormones (testosterone in males, estradiol in females). However, continuous exposure desensitizes and downregulates pituitary GnRH receptors, leading to profound suppression of gonadotropin release and near-castrate levels of sex hormones.

This biphasic effect underpins triptorelin's clinical applications in hormone-dependent conditions. In prostate cancer, testosterone suppression removes androgen stimulation of tumor growth. In endometriosis and uterine fibroids, estrogen suppression reduces disease activity. Controlled ovarian stimulation protocols use triptorelin to prevent premature LH surges during fertility treatment.

Depot formulations provide sustained release over one to six months, enabling convenient long-term hormone suppression. Research applications include studying GnRH receptor biology, investigating hormone-dependent disease mechanisms, and optimizing therapeutic protocols for various reproductive and oncological conditions.